NCT06045598

Brief Summary

The investigators aim to assess the postural control, ankle, and trunk proprioception, plantar sensation, and general cognitive status in patients with Type 2 diabetes.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
62

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2023

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2023

Completed
18 days until next milestone

Study Start

First participant enrolled

September 10, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

September 21, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 10, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

October 23, 2023

Status Verified

October 1, 2023

Enrollment Period

2 months

First QC Date

August 23, 2023

Last Update Submit

October 20, 2023

Conditions

Keywords

type 2 diabetespostural controlproprioceptionsensationcognition

Outcome Measures

Primary Outcomes (3)

  • Postural Control

    Postural control of the participants will be measured objectively by transferring the data taken from the body to the computer with the help of a wearable sensor using Gyko-Microgate software. Ellipsoid area and moving speed will be measured in mm² and mm/s².

    20 minutes

  • Ankle proprioception

    Proprioception in ankle plantar flexion and dorsiflexion will be measured with the help of a digital goniometer.

    10 minutes

  • Lumbal proprioception

    Proprioception in lumbar flexion and extension will be measured with the help of a digital goniometer.

    5 minutes

Secondary Outcomes (3)

  • Plantar sensation

    5 minutes

  • Cognitive status

    10 minutes

  • Dynamic Balance

    1 minute

Study Arms (2)

type 2 diabetes group

Participants between the ages of 18-65 who have been diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association (ADA).

Other: Semmes Weinstein Monofilament TestOther: Proprioception measurementOther: Postural control assessmentOther: Dynamic balance assessmentOther: Timed Up and Go TestOther: Montreal Cognitive Assessment

control group

Healthy participants between the ages of 18-65 who have not been diagnosed with Type 2 diabetes

Other: Semmes Weinstein Monofilament TestOther: Proprioception measurementOther: Postural control assessmentOther: Dynamic balance assessmentOther: Timed Up and Go TestOther: Montreal Cognitive Assessment

Interventions

The 10 g Semmes-Weinstein monofilament assessment (SWME) is used to assess sensory loss and screen for diabetic neuropathy. In our study, the evaluation will be made on the plantar surfaces of the 1st fingers, the plantar surfaces of the 1st, 3rd, and 5th metatarsal heads, and the plantar surfaces of the heel in the right and left feet. The first force value felt will be taken as the evaluation data.

control grouptype 2 diabetes group

Ankle proprioception will be measured with the participant's knees lying on their back in a semi-flexed position. The test will be performed for 10 degrees of dorsiflexion and 20 degrees of plantar flexion, respectively. Measurements will be made with an electrogoniometer device. The difference between the required degree and the degree in the position brought by the participant will be taken as evaluation data. Lumbal region proprioception measurement will be made with lumbar flexion and extension movements. The participant will be asked to perform active lumbar flexion. Then, lumbar flexion movement will be performed up to 50% of the measured active flexion angle and it will be requested to stay in this position for 10 seconds. After the participant returns to the upright position, he will be asked to come back to the learned angle and the difference in angle will be taken as evaluation data. The same procedure will be done for the lumbar extension movement.

control grouptype 2 diabetes group

Postural control evaluation will be done with the Gyko-Microgate software. Bluetooth data transmission enables real-time measurements to be transferred directly to the computer. After the device was placed on the body of the person thanks to the wearable vest, a connection was established with the software on the computer. To evaluate postural control, with eyes open, eyes closed and eyes open on a hard surface, accompanied by a cognitive dual task; On soft ground, with eyes open, eyes closed and eyes open, the person is asked to remain in a stable balance for 30 seconds, accompanied by a cognitive dual task. For the cognitive dual task, two countdowns and K-A-S verbal fluency exercises will be performed in each assessment. As a result of each evaluation, data on ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained.

control grouptype 2 diabetes group

Dynamic balance evaluation will be done with the Gyko device. To evaluate dynamic balance, walking with eyes open on hard ground, walking with cognitive dual task on hard ground; walking with eyes open on soft ground, and cognitive dual task on soft ground will be evaluated. The walking distance is determined as 6 meters. The first 1 meter and the last 1 meter will not be taken into consideration. The measurement will start at the 1st meter and end at the 5th meter. The measurement will be carried out at a distance of 4 meters. As a cognitive task, the participants will be given the task of counting down by two and K-A-S verbal fluency. As a result of each evaluation, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained.

control grouptype 2 diabetes group

The Timed Get Up and Walk Test is used to assess balance and fall risk. The participant stands up from the chair, walks 3 meters, turns back, and sits back on the chair. The time elapsed during these phases was recorded. In our study, the patient will be asked to start the test after the Gyko device is fixed with a wearable vest. During the test, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be taken.

control grouptype 2 diabetes group

MoCA is a 10-minute scale that measures global cognitive skills. It includes items consisting of attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation skills. The lowest score that can be obtained from the scale is 0, and the highest score is 30. Scores of 21 and below indicate the presence of cognitive impairment.

control grouptype 2 diabetes group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

31 patients between the ages of 18-65 who were diagnosed with Type 2 diabetes and 31 healthy participants who were not diagnosed with Type 2 diabetes, who applied to Hasan Kalyoncu University Application and Research Center, will participate in the study. All participants will be given detailed information about the study and signed a written informed consent form stating that they have voluntarily accepted the study.

You may qualify if:

  • Be between the ages of 18-65
  • Volunteering to participate in researc
  • Being diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association (ADA)

You may not qualify if:

  • Insufficient cognitive level
  • Traumatic nerve injury
  • Presence of congenital anomaly in the upper extremity
  • Presence of systematic disease (eg: rheumatological)
  • Having a problem involving the neurological system
  • Surgery involving the upper extremity in the last 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hasan Kalyoncu University

Gaziantep, 27000, Turkey (Türkiye)

RECRUITING

Hasan Kalyoncu University

Gaziantep, 27000, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • Gorniak SL, Lu FY, Lee BC, Massman PJ, Wang J. Cognitive impairment and postural control deficit in adults with Type 2 diabetes. Diabetes Metab Res Rev. 2019 Feb;35(2):e3089. doi: 10.1002/dmrr.3089. Epub 2018 Nov 8.

    PMID: 30338902BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Mental Status and Dementia Tests

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Neuropsychological TestsPsychological TestsBehavioral Disciplines and Activities

Central Study Contacts

Gunseli Usgu, Dr.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 23, 2023

First Posted

September 21, 2023

Study Start

September 10, 2023

Primary Completion

November 10, 2023

Study Completion

December 31, 2023

Last Updated

October 23, 2023

Record last verified: 2023-10

Locations